30th January 2023
Emil Lagumdzic joined the EIT Health SCI FI programme in 2022. Read more about his impressions and learnings and why you might want to join the next edition of this EIT Health programme for scientists.
Q: Why have you decided to join the SCI FI programme of EIT Health?
Emil Lagumdzic: I believe that collaboration between industry and academia is essential to maximize research and development, and this programme offers the opportunity to learn from real-life cases and work with experienced mentors in the pharma and medtech industries. As a PhD candidate in Immunology, I have decided to join the SCI FI programme of EIT Health because it aligns with my career goals of further developing my industry skills in this field. My previous experience working in the Cancer Research Center at Boehringer Ingelheim Vienna was very valuable and I wanted to continue to build on that experience.
Q: What new insights or skills have you learned during the programme?
EL: During the programme, I have learned valuable new insights and skills, such as design thinking, strategic management, market access, pricing, operational and project management, as well as soft skills like communication and collaboration, and creative skills like problem-solving, critical thinking and understanding customer and patient needs. I believe that these skills will be beneficial to me in my future career.
Q: Any personal highlights you would like to share with us?
EL: One personal highlight for me was the opportunity to work on a real business case for Roche Diagnostics Denmark, specifically on the topic of early diagnostics in lung cancer. It provided a valuable hands-on learning experience, allowing me to apply the skills and insights I had gained from the programme to a real-world scenario. Additionally, the opportunity to interact with talented scientists and industry partners from all over Europe was also a great opportunity to expand my professional network.
Q: How do you intend to use the learnings of the SCI FI programme in the future?
EL: I intend to use the learnings from the SCI FI Programme in the future by applying the skills and insights I have gained to my work in immunology. The programme has provided me with valuable experience and knowledge that I believe will enhance my research and development efforts and improve my ability to collaborate with industry partners. Additionally, the programme’s focus on medical device regulation, digital transformation and intellectual property will prove to be an asset in my field.
Q: To whom would you recommend the EIT Health SCI FI programme and why?
EL: I highly recommend the EIT Health SCI FI programme to young life scientists interested in innovation in life science and health, looking to transition to the pharma and medtech industries. The programme offers valuable skills and insights, real-life case studies, and the chance to work with experienced mentors. It also provides the opportunity to connect with talented scientists and industry partners from all over Europe. It is an ideal opportunity to enhance industry skills and advance in the field of innovation in life science and technology research.
Find out more about the SCI FI programme 2022 closing event hosted by EIT Health Partner Boehringer Ingelheim on our Linkedin Channel or find out more about the programme in general on eithealth.eu.
Corify Care raises €6M to revolutionise cardiac care
A significant milestone for the company.
Luminate Medical secures additional $2.5M to advance cancer care
A significant milestone for the company.
Longenesis teams up with Novartis for digital heart care innovation
Pilot project for treatment of cardiovascular diseases.